Logo.jpg
Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp
October 22, 2021 09:55 ET | Biofrontera AG
Leverkusen, Germany, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced the...
Logo.jpg
Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland
July 23, 2021 04:15 ET | Biofrontera AG
Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für...
Logo.jpg
Biofrontera AG reports completion of the clinical phase of the pharmacokinetics study
October 08, 2020 11:04 ET | Biofrontera AG
Leverkusen, Germany, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, reports the...
Logo_Biofrontera_AG.png
Biofrontera starts patient recruitment for U.S. Phase III Trial Evaluating Ameluz® / BF-RhodoLED® for Superficial Basal Cell Carcinoma
September 26, 2018 03:15 ET | Biofrontera AG
Enrollment of 186 patients at 12 study sites in the U.S. startedPhase III trial completion for photodynamic therapy of superficial basal cell carcinoma expected in first half of 2020Filing for...
Photodynamic Therapy Fundamentals Presented WAUSAU, Wis., March 22, 2013 (GLOBE NEWSWIRE) -- Laser 2013 will offer a session on Photodynamic Therapy, Friday, April 5, as part of the 33rd Annual Conference of the American Society for Laser...